유럽의 융합 유전자 검사 시장 : 분석 및 예측(2023-2033년)

“The Europe Gene Fusion Testing Market Expected to Reach $248.2 Million by 2033.”

Introduction to Europe Gene Fusion Testing Market

The Europe gene fusion testing market was valued at $71.4 million in 2023 and is anticipated to reach $248.2 million by 2033, witnessing a CAGR of 13.27% during the forecast period 2023-2033. The gene fusion testing market is anticipated to experience growth due to the increasing use of gene fusion testing for the advancement of targeted therapies.

Market Introduction

The gene fusion testing market in Europe is experiencing significant growth and evolution. This can be attributed to several factors, including the region's increasing focus on precision medicine and the development of targeted therapies. Gene fusion testing, which involves identifying genetic alterations that drive certain diseases, plays a pivotal role in tailoring treatments to individual patients. Europe's commitment to healthcare innovation and research is fostering advancements in gene fusion testing technologies, making them more accessible and accurate. Additionally, the region's strong pharmaceutical and biotechnology sectors are driving demand for these tests as they seek to develop novel therapeutics.

Furthermore, regulatory support and collaborations between research institutions and industry players are contributing to market expansion. As Europe continues to emphasize personalized medicine and molecular diagnostics, the gene fusion testing market in the region is poised for continued growth and innovation.

Market Segmentation:

Segmentation 1: by Indication

• Solid Tumors
• Hematological Malignancies

Segmentation 2: by Country

• U.K.
• Germany
• France
• Spain
• Italy
• Netherlands
• Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe gene fusion testing market (by indication) has been segmented into solid tumors and hematological malignancies. Moreover, the study provides the reader with a detailed understanding of the different indication of gene fusion testing in solid tumors.

Growth/Marketing Strategy: Gene fusion testing is a molecular diagnostic method employed to identify and analyze distinct genetic alterations in cancer cells. It arises when two distinct genes, typically from different chromosomes, abnormally join together, giving rise to a hybrid gene that generates a unique protein with modified functions.

Competitive Strategy: Key players in the Europe gene fusion testing market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the Europe gene fusion testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

Table of Contents

Executive Summary

1. Market Scope

• 1.1. Key Questions Answered in the Report

2. Research Methodology

3. Market Overview

• 3.1. Introduction to Gene Fusion Testing
  • 3.1.1. Different Technologies for Gene Fusion Testing
  • 3.1.2. Advantages and Limitations of Gene Fusion Testing
  • 3.1.3. Current Market Size and Future Growth Potential, $Million, 2022-2033
    • 3.1.3.1. Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion vs. Other Gene Fusions
  • 3.1.4. Role of Artificial Intelligence (AI) and Machine Learning (ML) in Gene Fusion Testing
  • 3.1.5. Reimbursement Landscape
• 3.2. Stakeholder's Survey Response
  • 3.2.1. Awareness of Gene Fusion Testing
  • 3.2.2. Familiarity with the NGS Offerings of the Following Companies
  • 3.2.3. Adoption and Barriers for Gene Fusion Testing

4. Industry Outlook

• 4.1. Regulatory Landscape
  • 4.1.1. Legal Requirements and Frameworks in Europe

5. Gene Fusion Testing Market (by Region), Value ($Million), 2022-2033

• 5.1. Overview
• 5.2. Europe
  • 5.2.1. Europe Gene Fusion Testing Market, by Indication
  • 5.2.2. Europe Gene Fusion Testing Market (by Country)
    • 5.2.2.1. Germany
      • 5.2.2.1.1. Germany Gene Fusion Testing Market (by Indication)
    • 5.2.2.2. France
      • 5.2.2.2.1. France Gene Fusion Testing Market (by Indication)
    • 5.2.2.3. U.K.
      • 5.2.2.3.1. U.K. Gene Fusion Testing Market (by Indication)
    • 5.2.2.4. Italy
      • 5.2.2.4.1. Italy Gene Fusion Testing Market (by Indication)
    • 5.2.2.5. Spain
      • 5.2.2.5.1. Spain Gene Fusion Testing Market (by Indication)
    • 5.2.2.6. Netherlands
      • 5.2.2.6.1. Netherlands Gene Fusion Testing Market (by Indication)
    • 5.2.2.7. Rest-of-Europe
      • 5.2.2.7.1. Rest-of-Europe Gene Fusion Testing Market (by Indication)

6. Markets - Competitive Benchmarking & Company Profiles

• 6.1. Overview
• 6.2. Biocartis
  • 6.2.1. Company Overview
  • 6.2.2. Role of Biocartis in the Gene Fusion Testing Market
  • 6.2.3. Key Competitors
  • 6.2.4. Recent Developments
  • 6.2.5. Financials
  • 6.2.6. Key Insights about the Financial Health of the Company
  • 6.2.7. Analyst Perspective
• 6.3. F. Hoffmann-La Roche Ltd.
  • 6.3.1. Company Overview
  • 6.3.2. Role of F. Hoffmann-La Roche Ltd in the Gene Fusion Testing Market
  • 6.3.3. Key Competitors
  • 6.3.4. Recent Developments
  • 6.3.5. Financials
  • 6.3.6. Key Insights about the Financial Health of the Company
  • 6.3.7. Analyst Perspective
• 6.4. OncoDNA
  • 6.4.1. Company Overview
  • 6.4.2. Role of OncoDNA in the Gene Fusion Testing Market
  • 6.4.3. Key Competitors
  • 6.4.4. Recent Developments
  • 6.4.5. Analyst Perspective
• 6.5. QIAGEN N.V.
  • 6.5.1. Company Overview
  • 6.5.2. Role of QIAGEN N.V. in the Gene Fusion Testing Market
  • 6.5.3. Key Competitors
  • 6.5.4. Recent Developments
  • 6.5.5. Financials
  • 6.5.6. Key Insights about the Financial Health of the Company
  • 6.5.7. Analyst Perspective